Figure 7
![Effect of dexamethasone or BPB on PLA2 activity activated by patient IgG. [H3] arachidonic acid was incorporated into platelet membrane phospholipid and incubated in the absence or presence of dexamethasone (as in Figure 5) in the presence of patient IgG, control IgG, or PLA2 inhibitor bromophenacyl bromide (BPB; 100 μM; n=3). SEM is given.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/6/10.1182_blood-2006-10-054064/7/zh80180707050007.jpeg?Expires=1722248245&Signature=uUzsM8cYOSgKbYdm5iXxmZOX9rJWDngka99Ayhac3sLBKGrXqfQWijAuIkFelCR2CU62Z3X~rTjql8hBH3-tOWUdgv74tCyhnxTJLMaNdRJ3-woxOFRy24I7QlPfIGiIJnWLBBo~q98FceyQM8IcyyguJHP5PURrhpH9DSrvbl0714Cf4NuqLKTAlBS8xY9ZPoocofF0W9h8SpQipVc-VbPg4HtPHYr0Si0cyPKORlM9LrZE37rjmuFDuG~CesEwae3SV9PmenaDqtkiGeYGD95elGWLB1ckjNr1iCSLp7Dv1UygjA3hCss3pGO9PtwJ8smGTwL4fuIYT~vOXwjZFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Effect of dexamethasone or BPB on PLA2 activity activated by patient IgG. [H3] arachidonic acid was incorporated into platelet membrane phospholipid and incubated in the absence or presence of dexamethasone (as in Figure 5) in the presence of patient IgG, control IgG, or PLA2 inhibitor bromophenacyl bromide (BPB; 100 μM; n=3). SEM is given.
